Edwards Lifesciences Corporation $EW Holdings Lifted by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 22.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,160 shares of the medical research company’s stock after acquiring an additional 10,169 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Edwards Lifesciences were worth $4,497,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $27,000. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock valued at $3,855,527 in the last three months. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.7%

EW stock opened at $83.21 on Tuesday. The company has a 50 day moving average of $87.74 and a two-hundred day moving average of $83.86. The company has a market cap of $47.91 billion, a price-to-earnings ratio of 47.82, a PEG ratio of 2.07 and a beta of 0.86. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on EW shares. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Barclays restated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.55.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.